vs

Side-by-side financial comparison of Arteris, Inc. (AIP) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Arteris, Inc. is the larger business by last-quarter revenue ($20.1M vs $19.6M, roughly 1.0× STANDARD BIOTOOLS INC.). Arteris, Inc. runs the higher net margin — -42.2% vs -177.4%, a 135.2% gap on every dollar of revenue. On growth, Arteris, Inc. posted the faster year-over-year revenue change (30.0% vs -11.5%). Arteris, Inc. produced more free cash flow last quarter ($3.0M vs $-23.1M). Over the past eight quarters, Arteris, Inc.'s revenue compounded faster (24.7% CAGR vs -12.2%).

Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

AIP vs LAB — Head-to-Head

Bigger by revenue
AIP
AIP
1.0× larger
AIP
$20.1M
$19.6M
LAB
Growing faster (revenue YoY)
AIP
AIP
+41.5% gap
AIP
30.0%
-11.5%
LAB
Higher net margin
AIP
AIP
135.2% more per $
AIP
-42.2%
-177.4%
LAB
More free cash flow
AIP
AIP
$26.1M more FCF
AIP
$3.0M
$-23.1M
LAB
Faster 2-yr revenue CAGR
AIP
AIP
Annualised
AIP
24.7%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AIP
AIP
LAB
LAB
Revenue
$20.1M
$19.6M
Net Profit
$-8.5M
$-34.7M
Gross Margin
90.8%
48.5%
Operating Margin
-42.0%
-168.5%
Net Margin
-42.2%
-177.4%
Revenue YoY
30.0%
-11.5%
Net Profit YoY
-3.7%
-28.8%
EPS (diluted)
$-0.19
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AIP
AIP
LAB
LAB
Q4 25
$20.1M
Q3 25
$17.4M
$19.6M
Q2 25
$16.5M
$21.8M
Q1 25
$16.5M
$40.8M
Q4 24
$15.5M
Q3 24
$14.7M
$22.1M
Q2 24
$14.6M
$22.5M
Q1 24
$12.9M
$45.5M
Net Profit
AIP
AIP
LAB
LAB
Q4 25
$-8.5M
Q3 25
$-9.0M
$-34.7M
Q2 25
$-9.1M
$-33.5M
Q1 25
$-8.1M
$-26.0M
Q4 24
$-8.2M
Q3 24
$-7.7M
$-26.9M
Q2 24
$-8.3M
$-45.7M
Q1 24
$-9.4M
$-32.2M
Gross Margin
AIP
AIP
LAB
LAB
Q4 25
90.8%
Q3 25
89.9%
48.5%
Q2 25
89.4%
48.8%
Q1 25
90.8%
48.4%
Q4 24
89.8%
Q3 24
90.1%
54.9%
Q2 24
90.0%
46.1%
Q1 24
88.7%
53.1%
Operating Margin
AIP
AIP
LAB
LAB
Q4 25
-42.0%
Q3 25
-50.1%
-168.5%
Q2 25
-50.0%
-118.1%
Q1 25
-46.6%
-80.8%
Q4 24
-45.9%
Q3 24
-53.8%
-120.9%
Q2 24
-51.1%
-134.5%
Q1 24
-70.5%
-132.2%
Net Margin
AIP
AIP
LAB
LAB
Q4 25
-42.2%
Q3 25
-51.6%
-177.4%
Q2 25
-55.3%
-153.7%
Q1 25
-49.1%
-63.8%
Q4 24
-53.0%
Q3 24
-52.2%
-122.0%
Q2 24
-57.2%
-203.3%
Q1 24
-72.6%
-70.6%
EPS (diluted)
AIP
AIP
LAB
LAB
Q4 25
$-0.19
Q3 25
$-0.21
$-0.09
Q2 25
$-0.22
$-0.09
Q1 25
$-0.20
$-0.07
Q4 24
$-0.19
Q3 24
$-0.20
$-0.07
Q2 24
$-0.22
$-0.12
Q1 24
$-0.25
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AIP
AIP
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$33.9M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$-14.6M
$399.7M
Total Assets
$115.0M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AIP
AIP
LAB
LAB
Q4 25
$33.9M
Q3 25
$39.0M
$129.4M
Q2 25
$38.0M
$158.6M
Q1 25
$42.3M
$150.9M
Q4 24
$43.8M
Q3 24
$48.7M
$210.6M
Q2 24
$45.8M
$269.8M
Q1 24
$44.8M
$287.1M
Total Debt
AIP
AIP
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
AIP
AIP
LAB
LAB
Q4 25
$-14.6M
Q3 25
$-11.4M
$399.7M
Q2 25
$-7.5M
$424.5M
Q1 25
$-4.8M
$454.6M
Q4 24
$-1.2M
Q3 24
$2.2M
$489.3M
Q2 24
$5.3M
$510.3M
Q1 24
$9.5M
$577.3M
Total Assets
AIP
AIP
LAB
LAB
Q4 25
$115.0M
Q3 25
$107.7M
$539.6M
Q2 25
$106.9M
$557.0M
Q1 25
$98.3M
$579.6M
Q4 24
$106.1M
Q3 24
$97.7M
$681.5M
Q2 24
$96.4M
$708.7M
Q1 24
$101.4M
$777.7M
Debt / Equity
AIP
AIP
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AIP
AIP
LAB
LAB
Operating Cash FlowLast quarter
$3.2M
$-22.2M
Free Cash FlowOCF − Capex
$3.0M
$-23.1M
FCF MarginFCF / Revenue
15.1%
-118.1%
Capex IntensityCapex / Revenue
0.7%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$5.3M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AIP
AIP
LAB
LAB
Q4 25
$3.2M
Q3 25
$3.2M
$-22.2M
Q2 25
$-2.5M
$-20.7M
Q1 25
$2.9M
$-30.3M
Q4 24
$-2.6M
Q3 24
$1.1M
$-27.9M
Q2 24
$311.0K
$-39.0M
Q1 24
$477.0K
$-62.5M
Free Cash Flow
AIP
AIP
LAB
LAB
Q4 25
$3.0M
Q3 25
$2.5M
$-23.1M
Q2 25
$-2.8M
$-22.6M
Q1 25
$2.7M
$-35.3M
Q4 24
$-2.7M
Q3 24
$1.1M
$-30.1M
Q2 24
$264.0K
$-41.0M
Q1 24
$281.0K
$-63.3M
FCF Margin
AIP
AIP
LAB
LAB
Q4 25
15.1%
Q3 25
14.2%
-118.1%
Q2 25
-17.2%
-103.6%
Q1 25
16.2%
-86.6%
Q4 24
-17.3%
Q3 24
7.4%
-136.4%
Q2 24
1.8%
-182.2%
Q1 24
2.2%
-138.9%
Capex Intensity
AIP
AIP
LAB
LAB
Q4 25
0.7%
Q3 25
4.1%
4.5%
Q2 25
2.2%
8.7%
Q1 25
1.1%
12.4%
Q4 24
0.3%
Q3 24
0.2%
10.2%
Q2 24
0.3%
8.6%
Q1 24
1.5%
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AIP
AIP

License And Maintenance$17.5M87%
Variable Royalties And Other$2.6M13%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons